Oruka Therapeutics, Inc. (ORKA) Q3 2025 10-Q Quarterly Report
Oruka Therapeutics, Inc. (ORKA) 10-Q quarterly report for Q3 2025, filed with SEC EDGAR on Nov 12, 2025 for the fiscal period ending Sep 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.
Oruka Therapeutics, Inc. Q3 2025 10-Q Analysis
Risk Factors
- • New risk: At-the-market equity offering program up to $200M initiated in Oct 2025 to raise capital amid market volatility and regulatory uncertainty
- • Updated risk: Clinical trial delays and potential increased costs highlighted due to slow enrollment and third-party contractor noncompliance risks
Get deeper insights on Oruka Therapeutics, Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.